Pembrolizumab OK'd for Cervical Cancer.
The FDA approved the PD-1 inhibitor pembrolizumab as a second-line treatment for patients with recurrent or metastatic cervical cancer who expressed PD-L1 with a combined positive score of at least 1. The approval was based on results of a phase II trial in which patients treated with the drug had an objective response rate of 14.3%.